Brief: Ironwood Pharmaceuticals Sees FY2023 Revenue $420 Mln-$435 Mln

Ironwood Pharmaceuticals

09/01/2023 11:12

Jan 9 (Reuters) - Ironwood Pharmaceuticals Inc  IRWD.O :
    * IRONWOOD PHARMACEUTICALS PROVIDES UPDATE ON FY 2022
FINANCIAL
GUIDANCE AND ANNOUNCES FY 2023 FINANCIAL GUIDANCE
    * EXPECTS 2023 ADJUSTED EBITDA OF GREATER THAN $250 MILLION
    * EXPECTS HIGH SINGLE-DIGIT LINZESS® EUTRX PRESCRIPTION
DEMAND
GROWTH IN 2023
    * EXPECT TO END 2022 WITH APPROXIMATELY $650 MILLION OF CASH
AND
CASH EQUIVALENTS ON BALANCE SHEET
    * SEES 2023 TOTAL REVENUE $420 - $435 MILLION
    * SEES FY 2022 TOTAL REVENUE ABOUT $411 MILLION
    * FY2022 REVENUE VIEW $421.9 MILLION -- REFINITIV IBES DATA
    * FY2023 REVENUE VIEW $439.3 MILLION -- REFINITIV IBES DATA

Source text for Eikon:  ID:nBwbc1K4za 
Further company coverage:  IRWD.O 
 ((Reuters.Briefs@thomsonreuters.com;))